606TiPRandomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. (23rd October 2018) - Kito, Y; Yamada, T; Matsumoto, T; Yasui, H; Murata, K; Makiyama, A; Hara, H; Baba, E; Nishio, K; Yoshimura, K; Hironaka, S; Muro, K; et al.